Status:
UNKNOWN
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Rectal Cancer, Adenocarcinoma
Chemoradiotherapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Control of the effect of prehabilitation on postoperative morbidity, assessed by the Comprehensive Complication Index (CCI), in patients diagnosed with rectal cancer that will receive neoadjuvant Quim...
Detailed Description
According to the annual report of the Spanish Medical Oncology Association (SEOM), in Spain and without differentiating by sex, colorectal cancer will be the cancer with the highest incidence by 2021;...
Eligibility Criteria
Inclusion
- Patient with rectal tumour and selected to initiate NRCT
- Patient must know the study and sign informed consent.
- Patient must accept the conditions necessaries to carry out the prehabilitation.
Exclusion
- Refusal of the patient to sign the informed consent.
- Baseline pathology that makes it impossible to carry out prehabilitation.
- Progression of the disease during the study period.
- Emergency surgery.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05286086
Start Date
March 1 2022
End Date
March 1 2025
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laura Mora López
Sabadell, Barcelona, Spain, 08208